Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 3/20 | 0.34 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | DAO | P14920 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
| ▸ | MARK3 | P27448 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 4/20 | 0.32 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.32 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.31 |
| ▸ | USP9X | Q93008 | 1/20 | 0.31 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL265894 | 1.00 | OGA (0.34) | OGANR3C1CHRM2CHRM1CHRNB2 | |
| SCHEMBL265893 | 1.00 | OGA (0.34) | OGANR3C1CHRM2CHRM1CHRNB2 | |
| SCHEMBL271525 | 0.90 | OGA (0.33) | OGANR3C1CHRM2CHRM1CHRNB2 | |
| SCHEMBL265048 | 0.87 | TRPV1 (0.37) | DAOP2RX7TRPV1TRPA1SCN5A | |
| SCHEMBL265047 | 0.87 | TRPV1 (0.37) | DAOP2RX7TRPV1TRPA1SCN5A | |
| SCHEMBL271533 | 0.86 | TRPV1 (0.38) | DAOP2RX7TRPV1TRPA1SCN5A | |
| SCHEMBL265026 | 0.85 | CHRM2 (0.33) | OGACHRM2CHRM1CHRNB2CHRM3 | |
| SCHEMBL271631 | 0.84 | BDKRB1 (0.33) | DAOP2RX7TRPV1TRPA1SCN9A | |
| SCHEMBL272169 | 0.84 | BDKRB1 (0.33) | DAOP2RX7TRPV1TRPA1SCN9A | |
| SCHEMBL13574545 | 0.83 | NR3C1 (0.34) | OGANR3C1P2RX7TRPV1TRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133909-B2 | Heteroaromatic monoamides as orexinin receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-03-13 | — | — | US | disclosed |
| EP-2297102-A1 | HETEROAROMATIC MONOAMIDES AS OREXININ RECEPTOR ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2011-03-23 | — | — | EP | disclosed |
| WO-2009153180-A1 | HETEROAROMATIC MONOAMIDES AS OREXININ RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-23 | — | — | WO | disclosed |
| US-20090312314-A1 | HETEROAROMATIC MONOAMIDES AS OREXININ RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312314-A1 | HETEROAROMATIC MONOAMIDES AS OREXININ RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPSR1 | OGA 2342/4885NR3C1 206/4885CHRM2 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.